Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?

J Oncol Pharm Pract. 2020 Jun;26(4):781-786. doi: 10.1177/1078155219856682. Epub 2019 Jun 25.

Abstract

Introduction: We aimed to investigate the impact of first biological agents on second-line biological agents in kras wild-type metastatic colon patients in right and left colon.

Patients and methods: The patients received anti-EGFR compared with anti-VEGF in right and left colon separately according to progression-free survival and overall survival in second line.

Results: A total of 84 patients were included in the study. In left colon, progression-free survival and overall survival were 9 and 14 months for anti-EGFR and 9 and 16 months for anti-VEGF in the second line. In right colon, progression-free survival and overall survival were 5 and 9 months for anti-EGFR and 4 and 6 months for anti-VEGF in the second line.

Conclusions: Progression-free survival was higher in patients who received bevacizumab first followed by anti-EGFR than reverse sequencing in right colon. Overall survival was similar between two groups.

Keywords: Metastatic colon cancer; anti-EGFR; anti-VEGF.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bevacizumab / administration & dosage
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Disease-Free Survival
  • ErbB Receptors / antagonists & inhibitors*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • KRAS protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • ErbB Receptors
  • Proto-Oncogene Proteins p21(ras)